Global assembling of Academicians, Researchers, Scholars & Industry to disseminate and exchange information at 100+ Allied Academics Conferences
Nitin TELANG earned his Ph.D. degree in 1974 from University of Poona, India, and obtained his post-doctoral training (1976-1985) in the USA at University of Nebraska, American Health Foundation, New York, and Memorial Sloan-Kettering Cancer Center, New York. He served on the faculty of Memorial Sloan-Kettering Cancer Center, Weill-Cornell Medical College, and Strang Cancer Prevention Center, New York (1986-2007). He serves as Director, Cancer Prevention Research Program at Palindrome Liaisons Consultants, New Jersey. Dr. TELANG has published more than 100 peer-reviewed papers and serves on the editorial boards of International Journal of Oncology, Oncology Reports and BMC-Complementary& Alternative Medicine.
Cancer stem cells represent a subpopulation of the primary cancer that is predominantly characterized by drug resistant phenotypes exhibiting tumorigenic potential. Long-term treatment options lead to emergence of drug resistant cancer stem cells. Relevant models for cancer stem cells facilitate novel experimental approaches that identify efficacy of stem cell targeted therapeutic agents. Experiments in the present study were designed to characterize stem cell models from molecular subtypes of clinical breast cancer.